1月29日上午，医疗器械板块再迎催化，脑机接口领域接连获2项重大标准立项。截至发稿，含"脑"量约 24%的医疗器械指数ETF（159898）盘中上涨0.88%、一度涨超1%；权重股奕瑞科技大涨6.61%，乐普 医疗涨超3%，成份股迪安诊断涨超7%，美好医疗、金域医学涨超5%，华大基因、祥生医疗等多股拉 升。 消息面上，1月28日消息，为满足监管急需，助推采用脑机接口技术的医疗器械高质量发展，经研究， 国家药监局批准《采用脑机接口技术的医疗器械范式设计与应用规范运动功能重建》《采用脑机接口技 术的医疗器械侵入式设备可靠性验证方法》等2项医疗器械行业标准制修订项目立项。 业内对此指出，这是对工信部等七部门此前发布的《关于推动脑机接口产业创新发展的实施意见》中标 准体系建设相关内容的具体落实，同时也结合行业反馈的共性难题实现了空白填补。 该机构分析强调，中证全指医疗器械指数精选103只成分股，重点聚焦创业板和科创板，覆盖医疗设 备、医疗耗材和体外诊断三大方向；指数质地纯粹，100%聚焦医疗器械细分板块，β属性纯正。"脑机 接口"概念暴露度达23.79%，对前沿医疗科技具备较好的布局优势；同时，指数成分股境外业务收入 ...

1月29日上午，医疗器械板块再迎催化，脑机接口领域接连获2项重大标准立项。截至发稿，含"脑"量约24%的医疗器械指数ETF（159898）盘中上涨 0.88%、一度涨超1%；权重股奕瑞科技大涨6.61%，乐普医疗涨超3%，成份股迪安诊断涨超7%，美好医疗、金域医学涨超5%，华大基因、祥生医疗等多股 拉升。 消息面上，1月28日消息，为满足监管急需，助推采用脑机接口技术的医疗器械高质量发展，经研究，国家药监局批准《采用脑机接口技术的医疗器械范式 设计与应用规范运动功能重建》《采用脑机接口技术的医疗器械侵入式设备可靠性验证方法》等2项医疗器械行业标准制修订项目立项。 业内对此指出，这是对工信部等七部门此前发布的《关于推动脑机接口产业创新发展的实施意见》中标准体系建设相关内容的具体落实，同时也结合行业反 馈的共性难题实现了空白填补。 此外，医疗器械指数ETF（159898）第四大权重股乐普医疗1月28日公告称，预计2025年归属于上市公司股东的净利润为8亿元-12亿元，比上年同期增长 223.97%-385.95%。主要因心血管植介入业务稳增、创新药及皮肤科等新兴板块贡献增量等。 万联证券指出，目前脑机接口正处于" ...

Group 1 - The medical device index ETF (159898) has shown strong performance, with a more than 2% increase in intraday trading, marking four consecutive days of gains, and a total net inflow of 342 million yuan over the past five trading days [1] - Strong Brain Technology, a Chinese brain-computer interface unicorn, has secretly submitted an IPO application in Hong Kong, potentially becoming the first listed company among the "Hangzhou Six Little Dragons," with a fundraising scale expected to reach several hundred million dollars [3] - The brain-computer interface sector is recognized as a significant technological breakthrough, with the national "14th Five-Year Plan" explicitly listing it as a future industry requiring forward-looking layout [3] Group 2 - The commercial pathway for brain-computer interfaces is expanding, with potential applications moving from medical rehabilitation to broader fields such as consumer electronics, smart homes, and industrial safety [3] - The global market for brain-computer interfaces is projected to exceed 10 billion dollars by 2030, with medical applications expected to dominate, and could grow to 145 billion dollars by 2040 [3] - The medical device index ETF (159898) tracks the CSI All-Share Medical Device Index, with 24% of its constituent stocks related to brain-computer interfaces, providing efficient coverage of this cutting-edge sector [4]

Group 1 - Nvidia and Eli Lilly will invest $1 billion over the next five years to establish an AI drug laboratory, focusing on accelerating medical discovery and production through robotics and physical AI [1] - The announcement has led to a significant rise in related pharmaceutical stocks, with Dean Diagnostics hitting the daily limit up for three consecutive trading days, and other companies like BGI Genomics and Berry Genomics seeing increases of over 16% and 8% respectively [1] - The medical device index ETF (159898) has gained 2.52% and has seen a net subscription of 366 million yuan over six consecutive days, indicating high market interest [1] Group 2 - Huafu Securities predicts that 2026 will mark the beginning of a new five-year period for AI healthcare, with expectations of more proactive fiscal signals supporting AI medical applications [2] - The current demand for AI applications in healthcare is expected to sustain the industry's long-term development, with recent events indicating a shift towards commercialization [2] - The National Medical Products Administration is expected to release ten measures by 2025-2026 to support the innovation and development of AI healthcare and high-end medical devices [2] Group 3 - The medical device index ETF (159898) tracks the CSI All-Share Medical Device Index, focusing entirely on the A-share medical device sector, with a pure beta quality [3] - The top ten holdings of the index include leading companies like Mindray Medical and United Imaging Healthcare, with over 80% of the portfolio in the ChiNext and STAR Market [3] Group 4 - The ETF's index includes a significant focus on brain-computer interface concepts, which account for approximately 24% of the index [4] - There is a scarcity of pure brain-computer interface stocks in the A-share market, presenting opportunities for capturing innovation in the industry [4] Group 5 - The medical device sector, which includes brain-computer interfaces, is expected to see substantial demand before and during the initial production phase of these technologies [5]

Core Insights - The brain-computer interface (BCI) sector is experiencing significant momentum driven by multiple catalysts, including investment inflows into the medical device index ETF, which has a 24% exposure to BCI-related companies [1][4] - The medical device index ETF (159898) has attracted 264 million CNY over five consecutive days, indicating strong investor interest [1][2] - Key stocks in the ETF, such as Di'an Diagnostics and Innotec, have shown substantial price increases, reflecting positive market sentiment towards the BCI sector [1][3] Investment Trends - The medical device index ETF (159898) has seen a high opening with a gain of over 1%, and several component stocks have experienced significant price increases, indicating a bullish trend in the market [1][3] - The ETF's structure allows for efficient exposure to the BCI sector, which is currently underrepresented in the A-share market [2][4] Industry Dynamics - The BCI market is expected to grow significantly, with projections indicating a global market size of approximately 2.62 billion USD in 2024, increasing to 12.4 billion USD by 2034, reflecting a compound annual growth rate of 17.35% [4] - Domestic policies are increasingly supportive of BCI development, with goals set for 2027 and 2030 to establish a competitive industry ecosystem [3][4] - Technological advancements in BCI, including new wireless implant systems, are enhancing the feasibility and efficiency of these devices, further driving market interest [3][4]

Core Insights - The announcement of the first non-invasive brain-computer interface (BCI) medical device registration in China marks a significant shift from laboratory research to clinical and market applications, indicating a new growth trajectory for the industry [1][2] - The medical device sector is experiencing a surge, with companies like Dean Diagnostics and Kingmed Diagnostics hitting their upper trading limits, reflecting strong market interest in BCI technologies [1][3] - The BCI sector is seen as a promising investment opportunity, with a clean chip structure and lower entry points compared to other tech sectors like satellites and chips [1] Industry Developments - The Chinese government has included BCI in its new five-year plan as a key future industry, signaling ongoing support for research and approval processes [2][3] - Major players in the industry are accelerating their efforts, with Neuralink announcing plans for large-scale production by 2026 and significant investments being made domestically [2][3] - Technological advancements in China, such as the ability for paralyzed patients to drink water using their thoughts, demonstrate the country's leadership in BCI technology [2] Market Dynamics - The BCI technology is categorized under medical devices, which are essential for addressing real and painful issues faced by patients, such as stroke recovery and spinal cord injuries [3][4] - The medical device index ETF (159898) includes approximately 24% of companies with substantial BCI business operations, providing an efficient investment vehicle for this emerging sector [3][4] - The medical device sector, which has faced declines over the past four years, is expected to see a turnaround driven by advancements in BCI technology [4]

Core Viewpoint - The years 2025 and 2026 are expected to witness significant historical milestones in the Chinese stock market, particularly with the Shanghai Composite Index breaking records and sectors like aerospace, non-ferrous metals, and brain-computer interfaces experiencing rapid growth [1]. Group 1: Satellite Industry - The satellite industry is currently in an unprecedented acceleration phase, with the satellite industry ETF (159218) being the first in the commercial aerospace sector to double in value this year [1]. - The International Telecommunication Union (ITU) has submitted an application for an additional 203,000 satellites, covering 14 satellite constellations, which indicates a potential doubling of satellite launches in 2026 compared to 2025 [4]. Group 2: Non-Ferrous Metals - The non-ferrous metals sector is poised for a new bull market in 2026, driven by the weakening of the US dollar and the increasing demand for materials like copper and rare earths, which are essential for electric vehicles, AI data centers, and high-end manufacturing [5]. Group 3: Brain-Computer Interfaces - The brain-computer interface sector is gaining attention due to its inclusion in the "14th Five-Year Plan" and significant advancements such as Neuralink's announcement of mass production in 2026 and successful clinical trials of domestic products [6]. - The most immediate application of brain-computer interfaces is in medical rehabilitation for patients with spinal injuries and strokes, highlighting the importance of practical applications over speculative concepts [8]. - The focus on brain-computer interfaces should be on high-end medical devices, as the sector is currently experiencing a policy and innovation cycle that supports its growth [8].

Group 1 - The core viewpoint of the article highlights the increasing market and funding attention towards brain-computer interfaces (BCIs), which are seen as a cutting-edge technology with significant future industry potential [2] - The medical device index ETF (159898) has seen a net inflow of over 170 million yuan in the last four trading days, with a single-day inflow exceeding 116 million yuan on January 8, marking a new high in its scale [2] - The medical device index ETF (159898) includes approximately 24% of companies with substantial involvement in the BCI sector, making it a convenient and efficient tool for investment in this emerging field [2][3] Group 2 - BCIs are interdisciplinary technologies that integrate neuroscience, computer science, and medicine, enabling direct communication between the brain and external devices [4] - Current applications of BCI technology are primarily in medical rehabilitation, particularly for patients recovering from strokes and spinal cord injuries, with potential future applications in education, entertainment, and industry [4] - The BCI sector is expected to experience strong growth driven by simultaneous advancements in policy, industry, and technology, with significant milestones anticipated by 2026 [7] Group 3 - The domestic BCI "unicorn" company, Qiangnao Technology, recently completed approximately 2 billion yuan in financing, becoming the second-largest financing in the BCI field globally, following Neuralink [7] - The Chinese government is actively supporting the BCI industry through various policies, emphasizing its importance as a key development area in the new five-year plan [7] - Recent breakthroughs in domestic BCI technology include successful clinical trials of fully implanted, wireless BCI products, indicating rapid advancements in the field [9] Group 4 - China's BCI market size grew from approximately 1 billion yuan in 2020 to about 1.73 billion yuan in 2023, representing a 12.5% share of the global BCI market [10] - Different institutions have varying growth forecasts for the BCI industry, with estimates suggesting the global market could reach 7.63 billion USD by 2029 [11] - The global BCI market is projected to grow to approximately 12.4 billion USD by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034 [14] Group 5 - BCIs are considered a potential key catalyst for driving upward trends in the medical device sector, supported by innovation and policy backing [15] - The medical device index ETF (159898) tracks the entire A-share medical device sector, with a pure representation of the industry and a 24% inclusion of BCI concepts, making it suitable for capturing opportunities in this emerging market [15]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth, driven by technological advancements and increased investment, particularly in the A-share market, with related stocks showing strong performance [1][5]. Group 1: Market Performance - The medical device index ETF (159898) has seen a rise of over 1.94%, with approximately 37 million yuan in net inflow as of the report [1]. - Key stocks in the BCI sector include Kewei Medical, which surged over 19%, and Shuoshi Bio, which increased over 13%, among others [3]. Group 2: Industry Growth - The global BCI market has grown from $1.2 billion in 2019 to nearly $2 billion in 2023, with a compound annual growth rate (CAGR) exceeding 13% [5]. - Projections indicate that the global BCI industry could reach $7.63 billion by 2029, with a CAGR of over 25% from 2024 to 2029 [5]. Group 3: Investment Opportunities - The BCI sector is positioned at a critical juncture with strong policy support, rapid technological iteration, and accelerated commercialization, making it a promising area for investment [8]. - The medical device index ETF (159898) tracks a broad range of medical device sectors, with leading companies like Mindray Medical and United Imaging Healthcare, providing a pure representation of the A-share medical device sector [8][9].

Core Viewpoint - The brain-computer interface (BCI) concept is significantly driving market interest, with notable stock price increases in related companies and a substantial inflow of funds into the medical device index ETF. Group 1: Market Performance - Companies such as Kefu Medical and Shuoshi Bio saw stock price increases of over 16% and 12% respectively, while several others rose by more than 6% [1] - The medical device index ETF (159898), which has a 24% exposure to the BCI concept, experienced a net inflow of over 100 million yuan during trading [1] Group 2: Industry Growth - The global BCI market size grew from $1.2 billion in 2019 to nearly $2 billion in 2023, with a compound annual growth rate (CAGR) exceeding 13% [3] - Forecasts suggest that the global BCI industry could reach $7.63 billion by 2029, with a projected CAGR of over 25% from 2024 to 2029 [3] Group 3: Investment Opportunities - The BCI sector is positioned as a key future industry, driven by technological breakthroughs, policy support, and collaboration within the robotics ecosystem [6] - The medical device index ETF tracks the CSI All-Share Medical Device Index, with significant holdings in leading companies like Mindray Medical, which has a 14.67% weight in the index [2][6]